GlassScriptPhysician profile
Roxanne Gail Carfora
NPI 1932204922
$8,442.58
in general payments reported to CMS, 2019-2025
21 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2020: $5,698 · 2021: $1,093 · 2022: $88.13 · 2023: $172 · 2024: $53.58 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Quidel Corporation | $5,020.21 | 2020 | |
| Novo Nordisk INC | $860.11 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $832.74 | 2019-2025 | |
| Amgen INC. | $432.59 | 2019 | |
| Pfizer INC. | $218.18 | 2019-2021 | |
| Amarin Pharma, INC. | $199.91 | 2019-2021 | |
| Alfasigma USA, INC. | $150.08 | 2020-2021 | |
| Allergan, INC. | $144.32 | 2019-2020 | |
| Revance Therapeutics, INC. | $128.38 | 2024-2025 | Daxxify |
| Ucb, INC. | $125.00 | 2023 | |
| Eisai INC. | $66.01 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.65 | 2021 | |
| Merz North America, INC. | $36.61 | 2025 | |
| Merck Sharp & Dohme LLC | $36.20 | 2019-2020 | |
| Clarus Therapeutics INC. | $28.56 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $26.10 | 2021 | |
| Ibsa Pharma INC. | $23.44 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $23.08 | 2020 | |
| Amag Pharmaceuticals, INC. | $19.68 | 2019 | |
| Vistapharm, INC. | $14.03 | 2021 | |
| Lilly USA, LLC | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Carfora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.